Hims & Hers (HIMS) shares gained 4% after adding Eli Lilly's Zepbound, Mounjaro, and Foundayo to its lineup. CEO Andrew Dudum compared the GLP-1 expansion to Netflix's early days. The platform now offers major treatments from both Eli Lilly and Novo Nordisk, with self-pay options available via membership.